A real-world study of prescription utilization of pregabalin for the treatment of zoster-associated pain
Objective To investigate the real-world use of pregabalin for zoster-associated pain(ZAP)in multiple hospitals in China.Methods Prescriptions for the use of pregabalin for the treatment of ZAP in the Hospital Prescription Analysis Collaborative Project from 2016 to 2021 were extracted.Information on patient gender,age,time,region,hospital level,department,combined disease,and drug combination in the prescriptions was compiled as sample data.The data were entered using Excel.The prescription data were statistically analyzed using SPSS 23.0 software.Factors influencing the administration of pregabalin in combination with other analgesics for the treatment of ZAP were analyzed by binary logistic regression.Results A total of 41 399 prescriptions were included.Data showed that there were more females who got the prescription than males,with more patients aged ≥ 60 years than those aged 18-59 years.The number of prescriptions was higher in first-tier cities than in non-first-tier cities and was significantly higher in tertiary hospitals than level-Ⅰ and level-Ⅱ hospitals.Pregabalin had been prescribed in all departments across the hospital,with the highest number of prescriptions in the department of dermatology and venereology.The number of prescriptions had increased year by year,with the fastest growth of 212.8％in 2018.22.2％of the patients had other combined diseases.81.3％of patients required combination treatment with other drugs,of which 33.9％received pregabalin combined with other analgesics.Regression analysis showed that female,≥ 60 years of age,first-tier city,tertiary hospital,outpatient,and combined disease were independent risk factors for pregabalin in combination with other analgesics(P＜0.05).Conclusion Pregabalin is widely used for the treatment of ZAP and often needs to be combined with other drugs or other analgesics.
PregabalinTreatmentZoster-associated painReal world
万方数据
维普
